Pfizer's Vyndaqel off and running thanks to diagnosis push by Eric Sagonowsky Tuesday, January 28, 2020 Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.
Pfizer's tafamidis poised for 'a decisive beat': analyst by Angus Liu Friday, October 18, 2019 With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.
